RxDoctor Payments DataLook up a doctor →

Joseph Arulandu, MD

Internal Medicine · la Porte, INNPI 1316952807

Payments from drug & device makers

$250,860in general payments, 2019–2025

Across 2,098 payments — averaging $119.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$104K
  • Amarin Pharma, Inc.$34K
  • Bayer$32K
  • Esperion Therapeutics, Inc.$28K
  • AstraZeneca$15K
  • Sanofi-aventis U.S. LLC$14K
  • plus $24K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk232$104,238
Amarin Pharma, Inc.77$34,347
Bayer87$31,641
Esperion Therapeutics, Inc.66$27,722
AstraZeneca113$14,611
Sanofi-aventis U.S. LLC54$13,696
AbbVie(2 entities)237$3,526
Medtronic(2 entities)48$1,550
Boehringer Ingelheim89$1,471
Pfizer105$1,410
Johnson & Johnson(2 entities)88$1,410
Amgen(2 entities)77$1,402
Lilly USA, LLC90$1,242
Merck66$962
GSK78$913
Novartis53$861
Takeda Pharmaceuticals U.S.A., Inc.48$673
Otsuka America Pharmaceutical, Inc.26$565
Mylan Specialty L.p.27$552
Astellas Pharma US Inc23$549
Corcept Therapeutics25$473
Insulet Corporation28$458
Corium, LLC20$420
Almatica Pharma LLC23$354
Dexcom, Inc.21$349
Axsome Therapeutics, Inc.13$340
Kowa Pharmaceuticals America, Inc.25$315
Antares Pharma, Inc.15$299
Vanda Pharmaceuticals Inc.8$279
Biohaven Pharmaceuticals, Inc.12$234
Biohaven Pharmaceutical Holding Company Ltd.12$232
Sumitomo Pharma America, Inc.13$219
Sunovion Pharmaceuticals Inc.17$217
Xeris Pharmaceuticals, Inc.10$167
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)9$166
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$163
Eisai Inc.10$160
Alkermes, Inc.8$153
Teva Pharmaceuticals USA, Inc.9$151
Phathom Pharmaceuticals, Inc.9$149
Viatris Specialty LLC8$143
Abbott9$130
Regeneron1$129
Lundbeck LLC7$124
Jazz Pharmaceuticals Inc.6$108
Recordati_rare_diseases_inc.4$101
United Therapeutics Corporation1$100
Supernus Pharmaceuticals, Inc.6$99
E.r. Squibb & Sons, L.L.C.7$97
Idorsia Pharmaceuticals US Inc6$96
Vertex5$92
Ironwood Pharmaceuticals, Inc6$81
Exact Sciences4$69
Alnylam Pharmaceuticals Inc.3$68
Neurocrine Biosciences, Inc.4$66
Biogen3$64
Radius Health, Inc.3$63
Paratek Pharmaceuticals, Inc.3$58
IBSA Pharma Inc.4$56
Ardelyx, Inc.3$51

How this compares

$250,860 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$175,457
Medicare patients
484
Services billed
2,809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in la Porte

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →